ReviewCancer metastasis reviews2025
Towards a personalized utilization of stereotactic body radiotherapy for the management of liver metastases in solid tumors.
Review in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial.The Lancet regional health. Europe · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of liver metastases in solid tumors is associated with poor prognosis. This adverse impact on patient outcomes may partly stem from the highly immunosuppressive environment commonly found within hepatic lesions, often resulting in a "cold" immune phenotype less responsive to immunotherapy. Despite this observation, the immune microenvironment of liver metastases is more complex and heterogeneous. Both intra- and inter-tumor heterogeneity are frequently observed in liver metastases. While multiple-site biopsies could potentially evaluate this heterogeneity, such procedures are invasive, time-consuming, and resource-intensive. Additionally, liquid biopsies based on circulating tumor DNA fail to provide insights into the immune landscape of individual lesions. The challenge of accurately evaluating the immune microenvironment of liver lesions at the individual level contributes to the variability in responses to immunotherapy-based treatments. Recent advances offer new opportunities to personalize the treatment of liver metastases. Radiomic signatures, in particular, offer a non-invasive means of assessing individual lesions' tumor texture, heterogeneity, and immune cell infiltration, such as the presence of CD8
Indexed as
Identifiers
41175290What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.